Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Int J Mol Sci ; 23(6)2022 Mar 12.
Article in English | MEDLINE | ID: mdl-35328489

ABSTRACT

Human neurohormone vasopressin (AVP) is synthesized in overlapping regions in the hypothalamus. It is mainly known for its vasoconstricting abilities, and it is responsible for the regulation of plasma osmolality by maintaining fluid homeostasis. Over years, many attempts have been made to modify this hormone and find AVP analogues with different pharmacological profiles that could overcome its limitations. Non-peptide AVP analogues with low molecular weight presented good affinity to AVP receptors. Natural peptide counterparts, found in animals, are successfully applied as therapeutics; for instance, lypressin used in treatment of diabetes insipidus. Synthetic peptide analogues compensate for the shortcomings of AVP. Desmopressin is more resistant to proteolysis and presents mainly antidiuretic effects, while terlipressin is a long-acting AVP analogue and a drug recommended in the treatment of varicose bleeding in patients with liver cirrhosis. Recently published results on diverse applications of AVP analogues in medicinal practice, including potential lypressin, terlipressin and ornipressin in the treatment of SARS-CoV-2, are discussed.


Subject(s)
COVID-19 Drug Treatment , Diabetes Insipidus/prevention & control , SARS-CoV-2/drug effects , Vasopressins/therapeutic use , Animals , Antidiuretic Agents/chemistry , Antidiuretic Agents/metabolism , Antidiuretic Agents/therapeutic use , COVID-19/epidemiology , COVID-19/virology , Deamino Arginine Vasopressin/chemistry , Deamino Arginine Vasopressin/metabolism , Deamino Arginine Vasopressin/therapeutic use , Diabetes Insipidus/metabolism , Hemostatics/chemistry , Hemostatics/metabolism , Hemostatics/therapeutic use , Humans , Lypressin/chemistry , Lypressin/metabolism , Lypressin/therapeutic use , Molecular Structure , Ornipressin/chemistry , Ornipressin/metabolism , Ornipressin/therapeutic use , Pandemics/prevention & control , SARS-CoV-2/metabolism , SARS-CoV-2/physiology , Terlipressin/chemistry , Terlipressin/metabolism , Terlipressin/therapeutic use , Vasopressins/chemistry , Vasopressins/metabolism
2.
Arch. Soc. Esp. Oftalmol ; 83(8): 487-492, ago. 2008. ilus
Article in Es | IBECS | ID: ibc-66874

ABSTRACT

Caso clínico: Presentamos el seguimiento de un caso de coroideremia que fue sometido a tres campos visuales automatizados blanco-blanco y tres polarimetrías láser (PL) con GDx VCC en el transcurso de un año. Se encontró un deterioro perimétrico en índices y escotomas. En concordancia, los parámetros de retardo de la capa de fibras nerviosas de la retina y los mapas cambiaron en un análisis serial avanzado con GDx VCC en los dos ojos. Discusión: El análisis con GDx VCC puede ser un método objetivo y cuantitativo para evaluar la progresión de las distrofias coriorretinianas como la coroideremia


Case report: We report the follow-up of a case of choroideremia who underwent three white-on-white automated visual field and three scanning laser polarimetry (SLP) examinations by means of a GDx VCC in the course of one year. A bilateral perimetric deterioration in indices and scotomas was found. As a result, retinal nerve fiber layer retardation parameters and maps changed on GDx VCC advanced serial analyses in both eyes. Discussion: Serial analyses with GDx VCC may be used as objective and quantitative tests to assess the progression of chorioretinal dystrophies like choroideremia (Arch Soc Esp Oftalmol 2008; 83: 487-492)


Subject(s)
Humans , Male , Middle Aged , Choroideremia/diagnosis , Choroideremia/epidemiology , Scotoma/complications , Scotoma/diagnosis , Scotoma/epidemiology , Ornipressin/therapeutic use , Fluorescein Angiography/methods , Lasers/therapeutic use , Laser Therapy/methods , Laser Therapy/statistics & numerical data , Laser Therapy/trends , Scotoma/pathology
3.
J Hepatol ; 40(1): 140-6, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14672625

ABSTRACT

BACKGROUND: Pretransplant renal function is the major determinant of survival after liver transplantation (LTx). Patients with hepatorenal syndrome (HRS) have a poor outcome after LTx compared with patients transplanted without HRS. AIM: To analyze the impact of treatment of HRS before LTx on outcome after transplantation. METHODS: The outcome of patients with HRS (n=9) treated with vasopressin analogues before LTx was compared with that of a contemporary control group of patients without HRS (n=27) matched by age, severity of liver failure, and type of immunosuppression. RESULTS: Cases and controls were similar with respect to pretransplantation characteristics. Three-year survival probability was similar between the two groups (HRS-treated: 100% vs control: 83%, P=0.15). No significant differences were found between the two groups with respect to the incidence of impairment of renal function after LTx (HRS-treated: 22% vs control: 30%), severe infections (22 vs 33%), acute rejection (33 vs 41%), days in Intensive Care Unit (6+/-1 vs 8+/-1), days in hospital (27+/-4 vs 31+/-4), and transfusion requirements (11+/-3 vs 10+/-2 units). CONCLUSIONS: Patients with HRS treated with vasopressin analogues before LTx have a posttransplantation outcome similar to that of patients transplanted with normal renal function. These results suggest that HRS should be treated before LTx.


Subject(s)
Hepatorenal Syndrome/drug therapy , Hepatorenal Syndrome/surgery , Liver Transplantation , Lypressin/analogs & derivatives , Vasopressins/therapeutic use , Case-Control Studies , Female , Hepatorenal Syndrome/physiopathology , Humans , Kidney/physiopathology , Liver Failure/surgery , Lypressin/therapeutic use , Male , Middle Aged , Ornipressin/therapeutic use , Postoperative Complications , Postoperative Period , Prognosis , Survival Analysis , Terlipressin , Treatment Outcome , Vasoconstrictor Agents/therapeutic use
10.
Anesth Analg ; 90(6): 1301-7, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10825311

ABSTRACT

UNLABELLED: We sought to evaluate the efficacy and side effect profile of a small dose of ornipressin, a vasopressin agonist specific for the V1 receptor, administered to reverse the hypotension associated with combined general/epidural anesthesia. A total of 60 patients undergoing intestinal surgery were studied. After the induction of anesthesia, 7-8 mL of bupivacaine 0.5% with 2 microg/kg clonidine and 0.05 microg/kg sufentanil after an infusion of 5 mL of bupivacaine 0.06% with 0.5 microg x kg(-1) x h(-1) clonidine and 0.1 microg/h of sufentanil were administered by an epidural catheter placed at T7-8 vertebral interspace. When 20% reduction of baseline arterial blood pressure developed, patients were randomly assigned to receive, in a double-blinded design, dopamine started at 2 microg x kg(-1) x min(-1), norepinephrine started at 0.04 microg x kg(-1) x min(-1), or ornipressin started at 1 IU/h. Fifteen patients presenting without hypotension were used as control subjects. Beside routine monitoring, S-T segment analysis, arterial lactacidemia, and gastric tonometry were performed. Ornipressin restored arterial blood pressure after 8 +/- 2 vs 7 +/- 3 min in the norepinephrine group and 11 +/- 3 min in the dopamine group (P < 0.05). This effect was achieved with 2 IU/h of ornipressin in most of the patients (11 of 15). Ornipressin did not induce any modification of the S-T segment; however, it significantly increased intracellular gastric PCO(2) (P < 0.05), indicating splanchnic vasoconstriction. IMPLICATIONS: In the population studied, small-dose ornipressin was effective to restore arterial blood pressure without causing major ischemic side effects.


Subject(s)
Anesthesia, Epidural , Anesthesia, General , Hypotension/chemically induced , Hypotension/drug therapy , Ornipressin/therapeutic use , Vasoconstrictor Agents/therapeutic use , Adolescent , Adult , Blood Gas Analysis , Blood Pressure/drug effects , Dopamine/therapeutic use , Double-Blind Method , Female , Heart Rate/drug effects , Humans , Male , Middle Aged , Monitoring, Intraoperative , Muscle Tonus/drug effects , Norepinephrine/therapeutic use , Splanchnic Circulation/drug effects , Stomach/drug effects
13.
Hepatology ; 30(4): 870-5, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10498636

ABSTRACT

Peripheral vasodilation is considered an important factor in the pathophysiology of the hepatorenal syndrome (HRS). Therefore, the aim of this study was to evaluate the therapeutic potential of the vasoconstrictor ornipressin plus dopamine in the treatment of the most severe form of HRS, namely HRS type 1. Seven cirrhotic patients (creatinine clearance 15 +/- 1 mL/min, UNaV 7 +/- 2 mmol/24 h) with HRS type 1 were included in the study after normalization of central venous pressure with intravenous albumin and low-dose dopamine had failed to prevent further deterioration of renal function. Ornipressin was given continuously (intravenous 6 IU/h) in combination with dopamine (2-3 microgram/kg/min) until creatinine clearance had increased to above 40 mL/min or adverse events prevented further treatment. HRS was reverted in 4 of 7 patients after 5 to 27 days (creatinine clearance 51 +/- 4 mL/min, UNaV 47 +/- 11 mmol/24 h) of treatment. Withdrawal was necessary in 1 patient after 15 days because of intestinal ischemia. Treatment failure was observed in 2 of 7 patients (creatinine clearance 19 +/- 10 mL/min, UNaV 8 +/- 3 mmol/24 h). Two of 4 responders had recidivant HRS 2 and 8 months after initial therapy, respectively. HRS in 1 of these patients was reverted with 18 days of ornipressin retreatment. The other patient had to be withdrawn from ornipressin after 2 hours because of ventricular tachyarrhythmia. Altogether, 3 of 7 patients survived HRS type 1, 1 after successful ornipressin therapy and liver transplantation, 1 with 2 successful courses of ornipressin, and 1 with liver transplantation after ornipressin treatment had failed. Thus, ornipressin plus dopamine can be a useful therapeutic option in patients with HRS type 1, especially as bridge to liver transplantation.


Subject(s)
Dopamine/therapeutic use , Hepatorenal Syndrome/drug therapy , Ornipressin/therapeutic use , Vasoconstrictor Agents/therapeutic use , Dopamine/adverse effects , Feasibility Studies , Female , Follow-Up Studies , Hemodynamics , Hepatorenal Syndrome/physiopathology , Hepatorenal Syndrome/surgery , Humans , Kidney/physiopathology , Liver/drug effects , Liver/physiopathology , Liver Transplantation , Male , Middle Aged , Ornipressin/adverse effects , Retreatment , Time Factors , Vasoconstrictor Agents/adverse effects
15.
Int J Oral Maxillofac Surg ; 27(6): 476-81, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9869292

ABSTRACT

A comparison of primary suturing and a new laser weld technique is described for the microsurgical repair of the inferior alveolar nerve in Wistar rats. A reliable method of exposure of the inferior alveolar nerve has been developed in order to allow intraosseous repairs of the nerve involving suturing with 10:0 nylon and a laser weld technique using an albumin-based solder, containing indocynine cardiogreen, plus an infrared (810 nm wavelength) diode laser. Seven cases of microsuture and laser weld repairs were performed with a 29.4% reduction in total operating time in the laser weld group. Histochemical analysis showed comparable mean neuron counts and mean tracer uptake by neurons for the microsuture and laser weld groups. Giant cell reactions were identified in two of the primary suture cases and axon deflection in three cases demonstrating possible advantages of the laser weld technique which showed no adverse reactions by axons or epineurium to the coagulative repair with the solder. The technique of laser weld repair, on initial analysis, therefore appears comparable with traditional suture repairs and indeed may possess several advantages. Further studies are recommended.


Subject(s)
Laser Coagulation/methods , Mandibular Nerve/surgery , Animals , Blood Loss, Surgical/prevention & control , Hemostatics/therapeutic use , Microsurgery/methods , Ornipressin/therapeutic use , Rats , Rats, Wistar , Serum Albumin, Bovine/administration & dosage , Suture Techniques , Trigeminal Nerve Injuries
17.
Hepatology ; 27(1): 35-41, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9425914

ABSTRACT

Hepatorenal syndrome is caused by a marked vasoconstriction of the renal circulation. It is suggested that the renal vasoconstriction is related to an overactivity of vasoconstrictor systems secondary to a vasodilation of the arterial circulation that causes a reduction in effective arterial blood volume. To test this hypothesis, 16 cirrhotic patients with hepatorenal syndrome were treated with a combination of ornipressin, a potent vasoconstrictor agent, and plasma volume expansion with albumin to improve effective arterial blood volume. The combined treatment was administered either for 3 or 15 days (8 patients each), and the effects on renal function, vasoactive systems, and systemic hemodynamics were assessed. The 3-day treatment with ornipressin and albumin was associated with a normalization of the overactivity of renin-angiotensin and sympathetic nervous systems, a marked increase in atrial-natriuretic peptide levels, and only a slight improvement in renal function. However, when ornipressin and albumin were administered for 15 days, a remarkable improvement in renal function was observed, with normalization of serum-creatinine concentration, a marked increase in renal plasma flow and glomerular filtration rate, and a persistent suppression in the activity of vasoconstrictor systems. However, 3 of 8 patients on 15-day therapy treatment had to be discontinued because of ischemic complications. In conclusion, the decrease in effective arterial blood volume and the activation of vasoconstrictor systems play a crucial role in the pathogenesis of hepatorenal syndrome. Although the prolonged administration of ornipressin combined with plasma volume expansion reverses hepatorenal syndrome, this treatment should be used with great caution in clinical practice because of the risk of ischemic complications.


Subject(s)
Hepatorenal Syndrome/therapy , Ornipressin/administration & dosage , Plasma Substitutes/therapeutic use , Serum Albumin/therapeutic use , Vasoconstrictor Agents/administration & dosage , Adult , Aged , Female , Hepatorenal Syndrome/physiopathology , Humans , Kidney/physiopathology , Male , Middle Aged , Norepinephrine/blood , Ornipressin/therapeutic use , Renin-Angiotensin System/physiology , Time Factors , Treatment Outcome , Vasoconstrictor Agents/therapeutic use
18.
Fertil Steril ; 68(5): 881-6, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9389820

ABSTRACT

OBJECTIVE: To determine the contribution of several variables to fluid loss during transcervical resection of submucous myomas. DESIGN: An observational study using multiple linear regression analyses. SETTING: A university-affiliated training hospital and a university department of clinical epidemiology and biostatistics. PATIENT(S): Patients with submucous myomas. INTERVENTION(S): Transcervical resection of submucous myomas and monitoring of fluid loss. MAIN OUTCOME MEASURE(S): Patient age, uterine enlargement, treatment with GnRH analogues or 8-ornithine-vasopressin, type of anesthesia, number of myomas, intramural extension of the myoma (type of myoma), and operating time were tested as variables. RESULT(S): Only intramural extension of the myoma and operating time were obviously related to fluid loss. For the other variables, such a relation was weak at best. The relation between fluid loss and operating time was not modified by any of the other variables. CONCLUSION(S): Because fluid loss is an important limiting factor in the transcervical resection of submucous myomas, special attention should be paid to reduction of the operating time and preoperative assessment of the intramural extension of the myoma to guide appropriate patient selection.


Subject(s)
Cervix Uteri , Leiomyoma/surgery , Uterine Neoplasms/surgery , Water-Electrolyte Imbalance/etiology , Adult , Female , Gonadotropin-Releasing Hormone/analogs & derivatives , Gonadotropin-Releasing Hormone/therapeutic use , Humans , Intraoperative Complications , Middle Aged , Ornipressin/therapeutic use , Regression Analysis , Risk Factors , Time Factors
19.
J Hepatol ; 25(6): 916-23, 1996 Dec.
Article in English | MEDLINE | ID: mdl-9007721

ABSTRACT

BACKGROUND/AIMS: Intravenous ornipressin in cirrhotic patients with hepatorenal syndrome causes marked improvement of systemic hemodynamics and suppression of plasma renin and norepinephrine but only moderate improvement of renal function. This study was designed to investigate whether these beneficial effects could be enhanced by the simultaneous administration of dopamine. The renal effects of the i.v. infusion of norepinephrine plus prostacyclin in patients with hepatorenal syndrome were also assessed. METHODS: Renal plasma flow, glomerular filtration rate, free water clearance, sodium excretion and the plasma levels of renin and norepinephrine were measured in baseline conditions and during the administration of ornipressin (6 i.u./h) and ornipressin (6 i.u./h) plus dopamine (2 micrograms/kg.min) in nine patients with hepatorenal syndrome. Five additional patients with hepatorenal syndrome were studied prior to and following the administration of norepinephrine (0.45 +/- 0.1 microgram/kg.min) and norepinephrine (0.85 +/- 0.2 microgram/kg.min) plus prostacyclin (5 ng/kg.min). RESULTS: Despite a significant increase in arterial pressure and marked suppression of plasma renin activity during ornipressin and ornipressin plus dopamine administration, no significant improvement in renal function was observed. Norepinephrine and norepinephrine plus prostacyclin also failed to increase renal perfusion and glomerular filtration rate. CONCLUSIONS: The combined administration of systemic vasoconstrictors (ornipressin or norepinephrine) and vasodilators (dopamine or prostacyclin), at the doses used in the current study and for a short period of time, does not improve renal function in cirrhotic patients with hepatorenal syndrome. The current study does not confirm a potential role for ornipressin in the treatment of hepatorenal syndrome.


Subject(s)
Antihypertensive Agents/administration & dosage , Dopamine/administration & dosage , Epoprostenol/administration & dosage , Hepatorenal Syndrome/physiopathology , Kidney/physiology , Liver Cirrhosis/physiopathology , Norepinephrine/blood , Ornipressin/administration & dosage , Vasoconstrictor Agents/administration & dosage , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Dopamine/therapeutic use , Drug Therapy, Combination , Epoprostenol/therapeutic use , Female , Glomerular Filtration Rate/drug effects , Hepatorenal Syndrome/blood , Hepatorenal Syndrome/drug therapy , Humans , Infusions, Intravenous , Kidney/drug effects , Liver Cirrhosis/blood , Liver Cirrhosis/drug therapy , Male , Middle Aged , Norepinephrine/administration & dosage , Ornipressin/therapeutic use , Renal Plasma Flow/drug effects , Renin/blood , Sodium/urine , Treatment Outcome , Vasoconstrictor Agents/therapeutic use
20.
Rev. Soc. obstet. ginecol. B.Aires ; 75(923): 374-82, dic. 1996. ilus
Article in Spanish | LILACS | ID: lil-205025

ABSTRACT

Se analiza la experiencia de un servicio de cirugía translaparoscópica (CTL) en embarazos intersticiales. Se trata de 5 casos resueltos totalmente por laparoscopia. Se describen los estudios prequirúrgicos necesarios. Su técnica quirúrgica y las maniobras necesarias para evitar un complicante sangrado. Destaca un abordaje conservador del mismo. Se informan datos sobre evolución reproductiva


Subject(s)
Humans , Female , Pregnancy , Adult , Pregnancy, Ectopic/surgery , Laparoscopy/standards , Abdominal Pain/etiology , Pregnancy, Ectopic/drug therapy , Pregnancy, Ectopic , Laparoscopy , Methotrexate , Methotrexate/therapeutic use , Ornipressin/adverse effects , Ornipressin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...